Fennec Pharmaceuticals Inc. (FENC) 是一家上市公司 属于 医疗保健 板块，经营于 生物科技 行业. 公司总部位于 Research Triangle Park, NC, 美国. 现任CEO为 Robert C. Andrade.
FENC 拥有 IPO日期为 2017-09-15, 32 名全职员工, 在 NASDAQ Capital Marke, 市值为 $178.63M.
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
